BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2026 10:07:37 AM | Browse: 157 | Download: 684
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 113440
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases
Manuscript Source Unsolicited Manuscript
All Author List En-Hui Dai, Shu-Hao Que, Huan Xu, Guo-Qiang Zhong, Zhen Zhang, Xu Liang, Shu-Wei Zhai, Yue-Tong Li, Jing-Jing Wang and Wei Feng
ORCID
Author(s) ORCID Number
Wei Feng http://orcid.org/0000-0001-8607-3697
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 82303672
Zhejiang Provincial Health Commission and Zhejiang Provincial Administration of Traditional Chinese Medicine through the Targeted Project for Medical and Health Research 2025ZL017
China Primary Health Care Foundation ZLMY20240311001ZJ
Corresponding Author Wei Feng, MD, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Gongshu District, Hangzhou 310022, Zhejiang Province, China. fengwei@zjcc.org.cn
Key Words Esophageal cancer; Liver metastasis; Chemotherapy; Immunotherapy; Local liver-directed therapy
Core Tip Although chemoimmunotherapy is the standard first-line treatment for metastatic esophageal cancer, its efficacy in the subgroup with liver metastases remains poorly characterized. This study demonstrated that chemoimmunotherapy significantly improved overall survival in this population, with a manageable safety profile. Key prognostic factors were identified, and the addition of local therapy to liver metastases may provide a rational approach to further optimize treatment outcomes.
Publish Date 2026-01-12 10:07
Citation

Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440

URL https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm
DOI https://dx.doi.org/10.4251/wjgo.v18.i1.113440
Full Article (PDF) WJGO-18-113440-with-cover.pdf